查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070493

伴侶動物藥品市場規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測。

Companion Animal Pharmaceuticals Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

伴侶動物藥品市場成長要素

全球伴侶動物藥品市場預計到2025年將達到213.8億美元，並從2026年的226億美元成長到2034年的388.7億美元，預測期內複合年成長率（CAGR）為7.02%。北美將引領全球市場，到2025年將佔40.73%的市場佔有率，這主要得益於北美地區較高的寵物擁有率、不斷成長的獸醫保健支出以及對先進寵物治療藥物日益成長的需求。

伴侶動物藥品包括處方藥、疫苗、驅蟲藥、皮膚病治療藥物、疼痛管理產品、感染疾病物以及針對犬、貓、鳥類和其他伴侶動物的慢性病治療藥物。寵物日益「人性化」、人們對預防性醫療保健意識的增強以及對高品質獸醫服務需求的不斷成長，是推動市場擴張的主要因素。此外，長效療法、單株抗體和廣譜抗寄生蟲產品的持續創新也加速了產業成長。

市場趨勢

寵物日益「擬人化」，推動了對高品質寵物護理的需求。

伴侶動物藥品市場最具影響力的趨勢之一是寵物「人性化」觀念的日益增強。寵物飼主越來越將寵物視為家庭成員，也更願意投資於能夠改善寵物生活品質和長期健康的先進療法。

這一趨勢正促使製藥公司開發針對骨關節炎、過敏性皮膚炎和腎臟病等慢性疾病的創新療法。長效生物製劑、單株抗體和特效療法的日益普及，正在將市場拓展到傳統預防保健產品之外，為生產商創造新的商機。

市場促進因素

寵物飼養量的增加正在推動市場擴張。

全球寵物數量的持續成長是推動伴侶動物藥品市場成長的主要因素。隨著伴侶動物數量的成長，對日常獸醫護理、疫苗接種、寄生蟲防治和慢性病管理的需求也隨之成長。

寵物飼主越來越希望找到方便、有效且全面的寵物治療方案。製藥公司不斷推出創新產品，拓展治療疾病範圍並改善用藥方式，推動了市場需求。新療法的法規核准和產品適應症的擴展也促進了市場的持續成長。

市場限制因素

高昂的獸醫醫療和藥品費用

獸醫服務和藥品成本的不斷上漲仍然是限制市場成長的主要阻礙因素。許多寵物飼主對價格非常敏感，可能會因為經濟原因而推遲就醫或中斷長期治療方案。

治療成本的上漲會對需要持續用藥和定期後續觀察的慢性病管理產生特別顯著的影響。隨著經濟挑戰的加劇，治療依從率可能會下降，對整體藥品銷售成長產生負面影響。

市場機遇

擴大寵物保險覆蓋範圍

寵物保險的日益普及為伴侶動物藥品生產商創造了巨大的商機。保險保障有助於減輕診斷、藥物、手術和長期疾病管理的經濟負擔。

隨著寵物保險普及率的提高，寵物飼主越來越傾向於接受先進的治療方案、特效藥物和預防保健計畫。這一趨勢有望提高治療的連續性，並促進品牌獸藥的更廣泛使用。

市場挑戰

複雜的監理核准要求

伴侶動物藥品生產商在監管合規和產品核可流程方面面臨許多挑戰。動物用藥品在上市前必須符合安全性、有效性、生產品質和上市後監測等方面的嚴格標準。

監管流程的複雜性往往會導致研發成本增加和產品上市時間延長。這些挑戰會減緩創新步伐，並延緩新療法的市場推廣。

細分市場分析

副產品

到2025年，動物用藥品領域將佔最大的市場佔有率，這主要得益於其在疼痛管理、皮膚病、寄生蟲感染疾病、心血管疾病和慢性病治療方面的廣泛應用。對治療藥物的持續需求將鞏固該領域的領先地位。

隨著人們對動物預防保健的日益關注，預計在預測期內，動物疫苗市場將以 9.26% 的複合年成長率成長。

動物物種

到 2025 年，由於獸醫就診頻率增加、預防保健產品普及以及獲批藥物治療的廣泛應用，犬類市場將佔主導地位。

受全球對貓科動物保健意識不斷提高的推動，預計到 2034 年，貓咪市場將以 8.00% 的複合年成長率成長。

透過行政途徑

預計口服製劑將在預測期內保持主導地位。口服藥片和咀嚼錠具有許多優勢，例如使用方便、能提高遵守用藥，並且便於寵物飼主進行長期治療。

預計在預測期內，氣溶膠領域的複合年成長率將達到 8.70%。

透過分銷管道

由於獸醫院在診斷、處方、治療後續觀察和產品推薦方面發揮著至關重要的作用，預計到 2025 年，獸醫醫院領域將佔最大的市場佔有率。

受動物用藥品可及性提高的推動，預計到 2034 年，藥局和藥局產業將以 8.70% 的複合年成長率成長。

區域展望

北美洲

預計北美將繼續保持其作為區域市場的領先地位，到 2025 年市場規模預計將達到 87.1 億美元。在寵物擁有率高、動物保健支出不斷增加以及先進動物保健產品普及的推動下，強勁成長預計將持續下去。

歐洲

預計2026年，歐洲寵物市場規模將達到56億美元，預測期內複合年成長率（CAGR）為6.73%。較高的寵物擁有率和完善的獸醫保健體係是推動市場擴張的主要因素。

亞太地區

預計到2026年，亞太地區市場規模將達到39.9億美元，成為成長最快的地區之一。可支配收入的成長、寵物擁有量的增加以及獸醫基礎設施的不斷完善，正在推動中國、日本和印度等主要國家的成長。

拉丁美洲、中東和非洲

預計到2026年，拉丁美洲市場規模將達到23.7億美元，而海灣合作理事會（GCC）市場預計將達到3.8億美元。人們對寵物醫療保健意識的提高和獸醫服務的改善將繼續推動該地區的發展。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要獸醫疾病的流行情況（按主要適應症、主要國家/地區分類）
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品發布等）
  • 主要國家和地區的監管狀況

第5章：全球伴侶動物藥品市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按產品分類。
    • 動物用藥品
      • 抗感染藥物
      • 消炎（藥）
      • 殺蟲劑
      • 其他
    • 動物疫苗
      • 失活
      • 減毒活病毒疫苗
      • 重組
      • 其他
  • 市場分析、洞察與預測：按動物類型分類
    • 貓
    • 狗
    • 鳥類
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
    • 外用
    • 氣霧劑
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 動物醫院
    • 動物診所
    • 藥局/藥局
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美伴侶動物藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲伴侶動物藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區伴侶動物藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲伴侶動物藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲伴侶動物藥品市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Zoetis Inc.
    • Elanco
    • Boehringer Ingelheim Animal Health
    • Merck Animal Health
    • Virbac
    • Vetoquinol SA
    • Ceva Sante Animale
    • Norbrook Laboratories Limited
    • Chanelle Pharma
    • Bimeda Animal Health Ltd.
Product Code: FBI116034

Growth Factors of companion animal pharmaceuticals Market

The global companion animal pharmaceuticals market size was valued at USD 21.38 billion in 2025 and is projected to grow from USD 22.60 billion in 2026 to USD 38.87 billion by 2034, exhibiting a CAGR of 7.02% during the forecast period. North America dominated the global market with a 40.73% market share in 2025, driven by high pet ownership rates, increasing veterinary healthcare expenditure, and growing demand for advanced pet therapeutics.

Companion animal pharmaceuticals include prescription medicines, vaccines, parasiticides, dermatology treatments, pain management products, anti-infectives, and chronic disease therapies designed for pets such as dogs, cats, birds, and other companion animals. Rising pet humanization, increasing awareness of preventive healthcare, and growing demand for premium veterinary treatments are major factors contributing to market expansion. Furthermore, continuous innovation in long-acting therapies, monoclonal antibodies, and broad-spectrum parasite control products is accelerating industry growth.

Market Trends

Rising Pet Humanization Driving Premium Therapeutic Demand

One of the most influential trends in the companion animal pharmaceuticals market is the growing humanization of pets. Pet owners increasingly consider animals as family members and are willing to invest in advanced treatments that improve quality of life and long-term health outcomes.

This trend is encouraging pharmaceutical companies to develop innovative therapies for chronic conditions such as osteoarthritis, allergic dermatitis, and kidney disease. The growing adoption of long-acting biologics, monoclonal antibodies, and specialty therapeutics is expanding the market beyond traditional preventive care products and creating new revenue opportunities for manufacturers.

Market Drivers

Rising Pet Ownership Supporting Market Expansion

The steady increase in global pet ownership is a primary factor driving companion animal pharmaceuticals market growth. As the number of companion animals rises, demand for routine veterinary care, vaccinations, parasite control, and chronic disease management also increases.

Pet owners are increasingly seeking convenient, effective, and comprehensive treatment options for their animals. Pharmaceutical companies continue to introduce innovative products with broader disease coverage and improved dosing convenience, further strengthening market demand. Regulatory approvals for new therapies and expanded product labels are also contributing to sustained market growth.

Market Restraints

High Veterinary Care and Medication Costs

The increasing cost of veterinary services and pharmaceutical treatments remains a major restraint for market growth. Many pet owners are becoming more price-sensitive and may delay veterinary visits or discontinue long-term treatment plans due to financial concerns.

Higher treatment costs can particularly affect chronic disease management, where ongoing medication and regular monitoring are required. As affordability challenges increase, treatment adherence may decline, impacting overall pharmaceutical sales growth.

Market Opportunities

Expanding Pet Insurance Coverage

Growing adoption of pet insurance is creating significant opportunities for companion animal pharmaceutical manufacturers. Insurance coverage helps reduce the financial burden associated with diagnostics, medications, surgeries, and long-term disease management.

As insurance penetration increases, pet owners are more likely to approve advanced treatments, specialty medicines, and preventive care programs. This trend is expected to improve treatment continuity and support higher utilization of branded veterinary pharmaceuticals.

Market Challenges

Complex Regulatory Approval Requirements

Companion animal pharmaceutical companies face significant challenges related to regulatory compliance and product approval processes. Veterinary medicines must meet strict standards for safety, efficacy, manufacturing quality, and post-market monitoring before commercialization.

The complexity of regulatory pathways often increases development costs and extends product launch timelines. These challenges can slow innovation and delay the introduction of new therapies into the market.

Segment Analysis

By Product

The veterinary drugs segment accounted for the largest market share in 2025 due to its extensive use in managing pain, dermatological conditions, parasitic infections, cardiovascular disorders, and chronic diseases. Continuous demand for therapeutic medications supports the segment's dominance.

The veterinary vaccines segment is expected to grow at a CAGR of 9.26% during the forecast period due to increasing focus on preventive animal healthcare.

By Animal Type

The canine segment dominated the market in 2025 owing to higher veterinary visit frequency, stronger adoption of preventive care products, and wider availability of approved pharmaceutical treatments.

The feline segment is projected to grow at a CAGR of 8.00% through 2034 as awareness regarding cat healthcare continues to increase globally.

By Route of Administration

The oral segment is expected to maintain market leadership throughout the forecast period. Oral tablets and chewable formulations offer greater convenience, improved compliance, and easier administration for pet owners managing long-term therapies.

The aerosol segment is anticipated to grow at a CAGR of 8.70% during the forecast period.

By Distribution Channel

The veterinary hospitals segment held the largest market share in 2025 due to their critical role in diagnosis, prescription, treatment monitoring, and product recommendation.

The pharmacies and drug stores segment is projected to expand at a CAGR of 8.70% through 2034, supported by increasing accessibility of veterinary medicines.

Regional Outlook

North America

North America remained the leading regional market with a valuation of USD 8.71 billion in 2025 and is projected to maintain strong growth due to high pet ownership, rising veterinary spending, and widespread adoption of advanced animal healthcare products.

Europe

Europe is projected to reach USD 5.60 billion in 2026 and grow at a CAGR of 6.73% during the forecast period. Strong pet ownership rates and well-established veterinary healthcare systems support market expansion.

Asia Pacific

Asia Pacific is expected to reach USD 3.99 billion in 2026 and emerge as one of the fastest-growing regions. Rising disposable incomes, increasing pet adoption, and expanding veterinary infrastructure are driving growth across major countries such as China, Japan, and India.

Latin America and Middle East & Africa

Latin America is projected to reach USD 2.37 billion in 2026, while the GCC market is expected to attain USD 0.38 billion. Growing pet healthcare awareness and improving veterinary services continue to support regional development.

Competitive Landscape

The companion animal pharmaceuticals market is highly consolidated, with major companies focusing on product innovation, acquisitions, strategic collaborations, and regulatory approvals to strengthen their market positions. Leading market participants include Zoetis Inc., Elanco, Boehringer Ingelheim Animal Health, Merck Animal Health, Virbac, Vetoquinol S.A., Ceva Sante Animale, Norbrook Laboratories, Chanelle Pharma, and Bimeda Animal Health Ltd.

Recent developments include approvals for innovative treatments targeting osteoarthritis, allergic dermatitis, chronic kidney disease, otitis externa, and parasite prevention. Companies are also investing in genomics, biologics, and personalized veterinary healthcare solutions to expand their product portfolios.

Conclusion

The companion animal pharmaceuticals market is witnessing steady growth as pet ownership rises and animals increasingly receive healthcare comparable to human family members. Growing demand for preventive care, chronic disease management, pain relief therapies, vaccines, and advanced biologics is supporting long-term market expansion. With the market projected to grow from USD 21.38 billion in 2025 to USD 38.87 billion by 2034, supported by increasing pet healthcare spending, expanding insurance coverage, and continuous pharmaceutical innovation, the industry is expected to remain one of the fastest-evolving segments within the global animal healthcare sector.

Segmentation By Product, Animal Type, Route of Administration, Distribution Channel, and Region

By Product * Veterinary Drugs

    • Anti-infectives
    • Anti-inflammatory
    • Parasiticides
    • Others
  • Veterinary Vaccines
    • Inactivated
    • Live Attenuated
    • Recombinant
    • Others

By Animal Type * Feline

  • Canine
  • Avian
  • Others

By Route of Administration * Oral

  • Parenteral
  • Topical
  • Aerosol
  • Others

By Distribution Channel * Veterinary Hospitals

  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region * North America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Veterinary Diseases, By Key Indication, By Key Countries /Regions
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Veterinary Drugs
      • 5.1.1.1. Anti-infectives
      • 5.1.1.2. Anti-inflammatory
      • 5.1.1.3. Parasiticides
      • 5.1.1.4. Others
    • 5.1.2. Veterinary Vaccines
      • 5.1.2.1. Inactivated
      • 5.1.2.2. Live Attenuated
      • 5.1.2.3. Recombinant
      • 5.1.2.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Animal Type
    • 5.2.1. Feline
    • 5.2.2. Canine
    • 5.2.3. Avian
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Aerosol
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Veterinary Hospitals
    • 5.4.2. Veterinary Clinics
    • 5.4.3. Pharmacies & Drug Stores
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Veterinary Drugs
      • 6.1.1.1. Anti-infectives
      • 6.1.1.2. Anti-inflammatory
      • 6.1.1.3. Parasiticides
      • 6.1.1.4. Others
    • 6.1.2. Veterinary Vaccines
      • 6.1.2.1. Inactivated
      • 6.1.2.2. Live Attenuated
      • 6.1.2.3. Recombinant
      • 6.1.2.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Animal Type
    • 6.2.1. Feline
    • 6.2.2. Canine
    • 6.2.3. Avian
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Aerosol
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Veterinary Hospitals
    • 6.4.2. Veterinary Clinics
    • 6.4.3. Pharmacies & Drug Stores
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Veterinary Drugs
      • 7.1.1.1. Anti-infectives
      • 7.1.1.2. Anti-inflammatory
      • 7.1.1.3. Parasiticides
      • 7.1.1.4. Others
    • 7.1.2. Veterinary Vaccines
      • 7.1.2.1. Inactivated
      • 7.1.2.2. Live Attenuated
      • 7.1.2.3. Recombinant
      • 7.1.2.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Animal Type
    • 7.2.1. Feline
    • 7.2.2. Canine
    • 7.2.3. Avian
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Aerosol
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Veterinary Hospitals
    • 7.4.2. Veterinary Clinics
    • 7.4.3. Pharmacies & Drug Stores
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Veterinary Drugs
      • 8.1.1.1. Anti-infectives
      • 8.1.1.2. Anti-inflammatory
      • 8.1.1.3. Parasiticides
      • 8.1.1.4. Others
    • 8.1.2. Veterinary Vaccines
      • 8.1.2.1. Inactivated
      • 8.1.2.2. Live Attenuated
      • 8.1.2.3. Recombinant
      • 8.1.2.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Animal Type
    • 8.2.1. Feline
    • 8.2.2. Canine
    • 8.2.3. Avian
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Aerosol
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Veterinary Hospitals
    • 8.4.2. Veterinary Clinics
    • 8.4.3. Pharmacies & Drug Stores
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Southeast Asia
    • 8.5.5. Australia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Veterinary Drugs
      • 9.1.1.1. Anti-infectives
      • 9.1.1.2. Anti-inflammatory
      • 9.1.1.3. Parasiticides
      • 9.1.1.4. Others
    • 9.1.2. Veterinary Vaccines
      • 9.1.2.1. Inactivated
      • 9.1.2.2. Live Attenuated
      • 9.1.2.3. Recombinant
      • 9.1.2.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Animal Type
    • 9.2.1. Feline
    • 9.2.2. Canine
    • 9.2.3. Avian
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Aerosol
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Veterinary Hospitals
    • 9.4.2. Veterinary Clinics
    • 9.4.3. Pharmacies & Drug Stores
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Veterinary Drugs
      • 10.1.1.1. Anti-infectives
      • 10.1.1.2. Anti-inflammatory
      • 10.1.1.3. Parasiticides
      • 10.1.1.4. Others
    • 10.1.2. Veterinary Vaccines
      • 10.1.2.1. Inactivated
      • 10.1.2.2. Live Attenuated
      • 10.1.2.3. Recombinant
      • 10.1.2.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Animal Type
    • 10.2.1. Feline
    • 10.2.2. Canine
    • 10.2.3. Avian
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Aerosol
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Veterinary Hospitals
    • 10.4.2. Veterinary Clinics
    • 10.4.3. Pharmacies & Drug Stores
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Zoetis Inc.
    • 11.2.2. Elanco
    • 11.2.3. Boehringer Ingelheim Animal Health
    • 11.2.4. Merck Animal Health
    • 11.2.5. Virbac
    • 11.2.6. Vetoquinol S.A.
    • 11.2.7. Ceva Sante Animale
    • 11.2.8. Norbrook Laboratories Limited
    • 11.2.9. Chanelle Pharma
    • 11.2.10. Bimeda Animal Health Ltd.

List of Tables

  • Figure 1: Global Companion Animal Pharmaceuticals Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025 & 2034
  • Figure 4: Global Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Companion Animal Pharmaceuticals Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Companion Animal Pharmaceuticals Market Value (USD billion), by Product, 2025 & 2034
  • Figure 8: North America Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025
  • Figure 9: North America Companion Animal Pharmaceuticals Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 10: North America Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025
  • Figure 11: North America Companion Animal Pharmaceuticals Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Companion Animal Pharmaceuticals Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Companion Animal Pharmaceuticals Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Companion Animal Pharmaceuticals Market Value Share (%), by Country, 2025
  • Figure 17: Europe Companion Animal Pharmaceuticals Market Value (USD billion), by Product, 2025 & 2034
  • Figure 18: Europe Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025
  • Figure 19: Europe Companion Animal Pharmaceuticals Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 20: Europe Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025
  • Figure 21: Europe Companion Animal Pharmaceuticals Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Companion Animal Pharmaceuticals Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Companion Animal Pharmaceuticals Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Companion Animal Pharmaceuticals Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Companion Animal Pharmaceuticals Market Value (USD billion), by Product, 2025 & 2034
  • Figure 28: Asia Pacific Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025
  • Figure 29: Asia Pacific Companion Animal Pharmaceuticals Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 30: Asia Pacific Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025
  • Figure 31: Asia Pacific Companion Animal Pharmaceuticals Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Companion Animal Pharmaceuticals Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Companion Animal Pharmaceuticals Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Companion Animal Pharmaceuticals Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America Companion Animal Pharmaceuticals Market Value (USD billion), by Product, 2025 & 2034
  • Figure 38: Latin America Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025
  • Figure 39: Latin America Companion Animal Pharmaceuticals Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 40: Latin America Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025
  • Figure 41: Latin America Companion Animal Pharmaceuticals Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Companion Animal Pharmaceuticals Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Companion Animal Pharmaceuticals Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Companion Animal Pharmaceuticals Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Companion Animal Pharmaceuticals Market Value (USD billion), by Product, 2025 & 2034
  • Figure 48: Middle East & Africa Companion Animal Pharmaceuticals Market Value Share (%), by Product, 2025
  • Figure 49: Middle East & Africa Companion Animal Pharmaceuticals Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 50: Middle East & Africa Companion Animal Pharmaceuticals Market Value Share (%), by Animal Type, 2025
  • Figure 51: Middle East & Africa Companion Animal Pharmaceuticals Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Companion Animal Pharmaceuticals Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Companion Animal Pharmaceuticals Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Companion Animal Pharmaceuticals Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Companion Animal Pharmaceuticals Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Companion Animal Pharmaceuticals Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global Companion Animal Pharmaceuticals Market Share (%), by Company, 2025